Humanized PMN310 Shows Significantly Greater Binding to The Toxic Oligomer Fraction of Alzheimer’s Disease Brain Extract Compared to Aducanumab
TORONTO and CAMBRIDGE, MA, Jan. 23, 2018 /PRNewswire/ – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and…
